SMO and ameloblastoma: BRAFV600E-mutant ameloblastomas presented at a much earlier age (mean age 42 years) as compared to SMO-mutated ameloblastomas, which was the oldest patient subgroup (mean age 67 years, rho = 0.299; p = 0.019).